In its first quarter 2024 results statement, Bristol Myers Squibb (NYSE: BMY) beat expectations on revenues, which increased 5% to $11.9 billion, although it posted a loss per share of $5.89, due to charges from recently-closed deals.
Those deals include a major oncology collab with China’s SystImmune, focused on antibody-drug conjugates (ADC), and the $14 billion acquisition of neurology specialist Karuna Therapeutics.
A large-scale “strategic productivity initiative” will be launched at the company, as the cancer giant moves to contain costs and build for future growth.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze